The lancet oncology
-
The lancet oncology · Feb 2015
Randomized Controlled Trial Multicenter Study Comparative StudyAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies. ⋯ Janssen Research & Development.
-
The lancet oncology · Feb 2015
Review Meta AnalysisAdjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.
The role of adjuvant chemotherapy for patients with rectal cancer after preoperative (chemo)radiotherapy and surgery is uncertain. We did a meta-analysis of individual patient data to compare adjuvant chemotherapy with observation for patients with rectal cancer. ⋯ None.
-
The lancet oncology · Feb 2015
Comparative StudyDisease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study.
Application of the principles of total mesorectal excision to colon cancer by undertaking complete mesocolic excision (CME) has been proposed to improve oncological outcomes. We aimed to investigate whether implementation of CME improved disease-free survival compared with conventional colon resection. ⋯ Tvergaards Fund and Edgar and Hustru Gilberte Schnohrs Fund.